Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Invion ( (AU:IVX) ).
Invion Limited has announced that its lead cancer drug candidate, INV043, has been granted Orphan Drug Designation by the US FDA for the treatment of anal cancer. This designation could significantly enhance Invion’s market positioning by potentially accelerating the drug’s development and approval process, impacting its operations positively and offering new opportunities for stakeholders.
More about Invion
Invion is a life-science company focused on the research and development of Photosoft technology for treating various cancers, atherosclerosis, and infectious diseases. It holds exclusive licensing rights in Australia, New Zealand, and parts of Asia Pacific for cancer indications and has expanded rights for atherosclerosis and infectious diseases in other regions. The company is listed on the ASX and its research is funded by RMW Cho Group Limited.
Average Trading Volume: 112,144
Technical Sentiment Signal: Sell
Current Market Cap: A$7.79M
See more data about IVX stock on TipRanks’ Stock Analysis page.